Figure 8.
Immune checkpoint blockade. (A) A total of 36 immune checkpoints, including PD-L1, PD-1, and CTLA-4, were differentially expressed between high- and low-risk patients. (B–E) Immunotherapeutic effect of anti-PD-1 and anti-CTLA-4 antibodies in high- and low-risk patients. (F) TIDE evaluation. (G) Dysfunction evaluation. (H–M) The prognostic performance of immunotherapy cohorts. ns, not significant; *p < 0.05; ***p < 0.001.